Catalent, Inc. Common Stock (NY:CTLT)

63.48 UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Catalent, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition

September 16, 2025

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable...

Via MarketMinute

Topics Earnings Economy Intellectual Property

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles ↗

August 25, 2025

Novo Nordisk's acquired facility faces scrutiny over recurring contamination, incomplete investigations, and ineffective corrective actions.

Via Benzinga

Beyond The Numbers: 6 Analysts Discuss Catalent Stock ↗

April 04, 2024

Via Benzinga

Lennox To Join S&P 500 Index, Replacing Catalent ↗

December 18, 2024

Lennox, an AI cooling play, will join the S&P 500 before the open on Dec. 23. Bill Holdings will take its pace in the S&P Midcap 400.

Via Investor's Business Daily

Topics Artificial Intelligence Stocks

Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent ↗

December 16, 2024

Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and operational impacts ahead.

Via Benzinga

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market ↗

December 05, 2024

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity.

Via Investor's Business Daily

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗

October 18, 2024

Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...

Via Benzinga

Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival ↗

October 15, 2024

Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities.

Via Benzinga

FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears ↗

October 10, 2024

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the merger could harm competition in the GLP-1 market, potentially driving up...

Via Benzinga

Four Stocks To Watch This Week - Tuesday, Oct. 01 ↗

October 01, 2024

A flat week that was anticipated, one notable event was China's stimulus package announcement, which sent China-related stocks soaring. Most of these stocks surged without prior consolidations/warning...

Via Talk Markets

Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

September 16, 2024

A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.

Via Investor's Business Daily

Topics Artificial Intelligence

Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater ↗

August 16, 2024

A small telemedicine company just entered the weight loss race.

Via The Motley Fool

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty ↗

June 21, 2024

Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.

Via Benzinga

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points ↗

June 01, 2024

Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry.

Via Investor's Business Daily

Topics Stocks

Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now? ↗

May 28, 2024

Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.

Via The Motley Fool

Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI ↗

May 24, 2024

Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI.

Via Benzinga

CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024 ↗

May 09, 2024

CTLT stock results show that Catalent missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.

Via InvestorPlace

Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition ↗

May 02, 2024

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly.

Via Benzinga

Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating ↗

April 12, 2024

BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled...

Via Benzinga

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics? ↗

March 26, 2024

All three of these high-flying stocks could have more room to run.

Via The Motley Fool

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗

March 23, 2024

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

Via Talk Markets

Did Novo Nordisk Just Get a Jump on Eli Lilly? ↗

March 19, 2024

A recent FDA announcement may have just put one company in the lead.

Via The Motley Fool

The Top 3 Pharma Stocks to Buy in March2024 ↗

March 09, 2024

Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.

Via InvestorPlace

Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug ↗

March 08, 2024

"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late...

Via Benzinga

Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk ↗

March 06, 2024

Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising...

Via Benzinga

Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why ↗

March 05, 2024

Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.

Via The Motley Fool

Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla ↗

March 01, 2024

U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones.

Via Benzinga

Topics ETFs Stocks

Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit) ↗

February 29, 2024

Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.